Merck & Co. (MRK) Given Average Recommendation of “Hold” by Analysts
Merck & Co. (NYSE:MRK) has been assigned an average rating of “Hold” from the twenty-two brokerages that are currently covering the stock. Thirteen investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is €64.86 ($71.27).
Several equities research analysts have issued reports on MRK shares. BMO Capital Markets reiterated an “outperform” rating and set a $62.00 price objective on shares of Merck & Co. in a research note on Tuesday, June 28th. Vetr upgraded shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 target price for the company in a research note on Monday, July 4th. Credit Suisse Group AG restated a “hold” rating and issued a $59.00 target price on shares of Merck & Co. in a research note on Wednesday, July 6th. Leerink Swann restated a “hold” rating and issued a $58.00 target price on shares of Merck & Co. in a research note on Thursday, July 14th. Finally, Jefferies Group upped their target price on shares of Merck & Co. from $50.00 to $53.00 and gave the company a “hold” rating in a research note on Thursday, July 14th.
Shares of Merck & Co. (NYSE:MRK) traded down 0.925% on Monday, reaching $61.565. 7,050,396 shares of the company’s stock traded hands. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.86. The company has a 50 day moving average of $62.56 and a 200-day moving average of $58.70. The stock has a market capitalization of $170.24 billion, a PE ratio of 33.771 and a beta of 0.68.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/merck-co-mrk-given-average-recommendation-of-hold-by-analysts.html
Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The company earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the firm earned $0.86 earnings per share. Merck & Co.’s revenue for the quarter was up .6% on a year-over-year basis. Equities research analysts forecast that Merck & Co. will post $3.75 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 15th were given a $0.46 dividend. The ex-dividend date was Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.96%. Merck & Co.’s dividend payout ratio is presently 101.10%.
In related news, Chairman Kenneth C. Frazier sold 392,000 shares of the stock in a transaction dated Friday, August 5th. The shares were sold at an average price of €61.81 ($67.92), for a total value of €24,229,520.00 ($26,625,846.15). Following the completion of the transaction, the chairman now owns 760,877 shares in the company, valued at approximately €47,029,807.37 ($51,681,107). The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Weir Mirian M. Graddick sold 40,800 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of €62.07 ($68.21), for a total transaction of €2,532,456.00 ($2,782,918.68). Following the completion of the transaction, the insider now owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,797,092.43). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Merck & Co. by 1.9% in the second quarter. Vanguard Group Inc. now owns 174,819,694 shares of the company’s stock worth $10,071,362,000 after buying an additional 3,242,254 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Merck & Co. by 0.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 74,363,785 shares of the company’s stock worth $4,284,098,000 after buying an additional 535,407 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Merck & Co. by 4.0% in the second quarter. BlackRock Fund Advisors now owns 44,732,600 shares of the company’s stock worth $2,577,045,000 after buying an additional 1,701,520 shares in the last quarter. BlackRock Group LTD raised its position in shares of Merck & Co. by 2.0% in the first quarter. BlackRock Group LTD now owns 27,068,748 shares of the company’s stock worth $1,432,206,000 after buying an additional 525,220 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Merck & Co. by 6.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 26,224,184 shares of the company’s stock worth $1,510,776,000 after buying an additional 1,531,565 shares in the last quarter. Hedge funds and other institutional investors own 72.93% of the company’s stock.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.